187 results on '"Yang, Sherry X."'
Search Results
2. Locoregional tumor burden and risk of mortality in metastatic breast cancer
3. Upregulation of TET2 and Resistance to DNA Methyltransferase (DNMT) Inhibitors in DNMT1 -Deleted Cancer Cells.
4. TET2 and DNMT3A mutations and exceptional response to 4′-thio-2′-deoxycytidine in human solid tumor models
5. Targeting BCR-ABL in Chronic Myelogenous Leukemia
6. Hormone Receptors and Endocrine Therapy in Breast Cancer
7. Overview of Therapeutic Biomarkers in Cancer
8. Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up
9. Abstract LB119: Recurrence score for recurrence over survival outcome in the landmark TAILORx trial
10. Data from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
11. Supplementary Table 2 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
12. Supplementary Table 7 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
13. Supplementary Table 5 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
14. Supplementary Table 1 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
15. Supplementary Table 3 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
16. Supplementary Table 4 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
17. Supplementary Table 6 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
18. Supplementary Figure 3 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
19. Data from Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer
20. Supplementary Figure 1 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
21. Supplementary Methods, Tables 1 - 3 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
22. Supplementary Figure 2 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
23. Supplementary Tables S1-S2 from Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer
24. Supplementary Table 1 from Gene Expression Patterns and Profile Changes Pre- and Post-Erlotinib Treatment in Patients with Metastatic Breast Cancer
25. Supplementary Figure 6 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
26. Supplementary Figure 5 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
27. Supplementary Figure 4 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
28. Abstract P2-11-09: Association of 21-gene recurrence score with overall survival in phase 3 TAILORx trial
29. Development and Validation of a Nomogram for Early Detection of Malignant Gallbladder Lesions
30. Abstract LB192: Demethylation, DNA damage and antitumor activity of DNA methyltransferase inhibitors in models with intact and disrupted DNMT1 gene
31. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors
32. Evaluation of Lymphangiogenic Factors, Vascular Endothelial Growth Factor D and E-Cadherin in Distinguishing Inflammatory From Locally Advanced Breast Cancer
33. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
34. Additional file 1 of TET2 and DNMT3A mutations and exceptional response to 4′-thio-2′-deoxycytidine in human solid tumor models
35. Dihydropyrimidine Dehydrogenase Deficiency and 5-Fluorouracil-Toxicity
36. The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer
37. Targeting Notch signaling pathway in cancer: Clinical development advances and challenges
38. Abstract LB-107: TET2/DNMT3A mutations and exceptional response to novel epigenetic agent in human malignancies
39. Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer
40. Bevacizumab and breast cancer: current therapeutic progress and future perspectives
41. A Pilot Study to Evaluate the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor AZD2171 and Chemotherapy in Locally Advanced and Inflammatory Breast Cancer
42. Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer
43. Epidermal Growth Factor Receptor Expression in Breast Cancer
44. Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer
45. Abstract 3847: Knockout of DNMT1 using CRISPR gene-editing technology confers resistance to DNMT inhibitors in human breast cancer cells
46. p53 expression and clinical outcomes in untreated and treated breast cancer patients after long-term follow-up.
47. Expression of Gli1 in the hedgehog signaling pathway and breast cancer recurrence
48. Abstract 5081: Disruption of DNA methyltransferase (DNMT) 1 confers resistance to DNMT inhibitors in human colorectal cancer cells
49. Survival profile in breast cancer molecular subtypes without systemic and locoregional treatment.
50. Association of γH2AX at Diagnosis with Chemotherapy Outcome in Patients with Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.